Helix BioPharma Corp. (TSX:HBP), a clinical-stage biopharmaceutical company has announced the appointment of Dr Frank Gary Renshaw to the company's Scientific Advisory Board.
The company noted that Dr Renshaw is a healthcare industry executive and Oncologist-Hematologist drug developer with several decades of oncology drug development experience. He has provided medical and scientific expertise ranging from early-stage pre-clinical drug development to presiding over dozens of successful US. investigational new drug applications and European Medical Agency new drug submissions of which some have resulted in successful new drug applications.
READ: Helix BioPharma closes divesture of Polish subsidiary
Dr Renshaw is currently the chief medical officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. He also participates in a number of oncology industry committees and task forces.
"We are very excited to welcome Dr Renshaw to the Company's Scientific Advisory Board, said Dr Heman Chao, Helix's chief executive and science officer in a statement. "Dr Renshaw brings a wealth of experience in oncology drug development and medical expertise to Helix. I look forward to working with the Scientific Advisory Board in continuing the advancement of L-DOS47 in the clinic."
Helix BioPharma is developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer-based on our proprietary technological platform DOS47.
Contact the author at jon.hopkins@proactiveinvestors.com